ALNYLAM Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ALNYLAM, and when can generic versions of ALNYLAM drugs launch?
ALNYLAM has four approved drugs.
There are forty-four US patents protecting ALNYLAM drugs.
There are seven hundred and seventy patent family members on ALNYLAM drugs in fifty-four countries and seventy-five supplementary protection certificates in seventeen countries.
Drugs and US Patents for ALNYLAM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | RX | Yes | Yes | 10,119,143 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | RX | Yes | Yes | 8,158,601 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | RX | Yes | Yes | 11,530,408 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ALNYLAM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | 8,895,718 | ⤷ Try a Trial |
Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | 8,552,171 | ⤷ Try a Trial |
Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | 8,362,231 | ⤷ Try a Trial |
Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | 9,708,615 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ALNYLAM Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
China | 109112131 | ⤷ Try a Trial |
China | 108064154 | ⤷ Try a Trial |
Cyprus | 2019005 | ⤷ Try a Trial |
South Korea | 20220012422 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ALNYLAM Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3581654 | 2021C/534 | Belgium | ⤷ Try a Trial | PRODUCT NAME: LUMASIRAN; AUTHORISATION NUMBER AND DATE: EU1/20/1496 20201123 |
3329002 | 301216 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: VUTRISIRAN; REGISTRATION NO/DATE: EU/1/22/1681 20220916 |
2937418 | PA2019501 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: PATISIRANAS; REGISTRATION NO/DATE: EU/1/18/1320 20180827 |
3581654 | 38/2021 | Austria | ⤷ Try a Trial | PRODUCT NAME: LUMASIRAN; REGISTRATION NO/DATE: EU/1/20/1496 (MITTEILUNG) 20201123 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.